Looks like there`s been an error while trying to load this page.
Our team has been notified but please contact us using the email support widget if the problem persists.
| Metrics | Range | Conclusion |
|---|---|---|
| Selected LTM Ps Multiple | 1.3x - 1.5x | 1.4x |
| Selected Fwd Ps Multiple | 3.0x - 3.3x | 3.2x |
| Fair Value | ₪0.029 - ₪0.032 | ₪0.030 |
| Upside | 36.9% - 51.3% | 44.1% |
| Benchmarks | Ticker | Full Ticker |
|---|---|---|
| Kamada Ltd. | - | TASE:KMDA |
| Can-Fite BioPharma Ltd. | - | TASE:CANF |
| Pluri Inc. | - | TASE:PLUR |
| XTL Biopharmaceuticals Ltd. | - | TASE:XTLB |
| Compugen Ltd. | - | TASE:CGEN |
| BioLineRx Ltd. | - | TASE:BLRX |
| Select Price / LTM Sales Ratio | ||||||||
| Benchmark Companies | ||||||||
| KMDA | CANF | PLUR | XTLB | CGEN | BLRX | |||
| TASE:KMDA | TASE:CANF | TASE:PLUR | TASE:XTLB | TASE:CGEN | TASE:BLRX | |||
| Historical Sales Growth | ||||||||
| 5Y CAGR | 4.8% | -19.8% | 43.3% | NM- | NM- | NM- | ||
| 3Y CAGR | 15.8% | -7.6% | NM- | NM- | 66.8% | NM- | ||
| Latest Twelve Months | 9.7% | -16.0% | 309.8% | NM | -48.2% | 1.2% | ||
| Historical Net Income Profit Margin | ||||||||
| 5 Year Average Margin | 4.7% | -1358.1% | -25746.9% | -1261.7% | -505.1% | -292.0% | ||
| Prior Fiscal Year | 5.8% | -1027.5% | -9867.9% | NA | -56.1% | -1262.8% | ||
| Latest Fiscal Year | 9.0% | -1169.1% | -6407.4% | -227.7% | -51.1% | -31.9% | ||
| Latest Twelve Months | 11.2% | -1571.3% | -2003.3% | -227.7% | -87.4% | -45.3% | ||
| Current Trading Multiples | ||||||||
| EV / LTM EBITDA | 9.0x | -0.9x | -2.6x | -4.9x | -1.8x | 0.0x | ||
| Price / LTM Sales | 2.4x | 25.3x | 35.8x | 24.0x | 5.7x | 0.9x | ||
| LTM P/E Ratio | 21.0x | -1.6x | -1.8x | -10.5x | -6.5x | -2.1x | ||
| Low | Mid | High | ||||||
| Benchmark LTM P/S Ratio | 2.4x | 24.0x | 35.8x | |||||
| Historical LTM P/S Ratio | 1.1x | 1.1x | 1.1x | |||||
| Selected Price / Sales Multiple | 1.3x | 1.4x | 1.5x | |||||
| (x) LTM Sales | 17 | 17 | 17 | |||||
| (=) Equity Value | 23 | 24 | 26 | |||||
| (/) Shares Outstanding | 2,557.6 | 2,557.6 | 2,557.6 | |||||
| Implied Value Range | 0.01 | 0.01 | 0.01 | |||||
| FX Rate: USD/ILS | 0.3 | 0.3 | 0.3 | Market Price | ||||
| Implied Value Range (Trading Cur) | 0.03 | 0.03 | 0.03 | 0.02 | ||||
| Upside / (Downside) | 44.5% | 52.1% | 59.7% | |||||
| Equity Value | |||||||
| Benchmark Companies | |||||||
| (in millions) | KMDA | CANF | PLUR | XTLB | CGEN | BLRX | |
| Value of Common Equity | 400 | 14 | 37 | 11 | 128 | 16 | |
| (/) Shares Outstanding | 57.7 | 4,731.9 | 7.9 | 881.4 | 93.5 | 2,557.6 | |
| Implied Stock Price | 6.93 | 0.00 | 4.67 | 0.01 | 1.37 | 0.01 | |
| FX Conversion Rate to Trading Currency | 0.30 | 0.30 | 0.30 | 0.30 | 0.30 | 0.30 | |
| Implied Stock Price (Trading Cur) | 23.16 | 0.01 | 15.59 | 0.04 | 4.57 | 0.02 | |
| Trading Currency | ILS | ILS | ILS | ILS | ILS | ILS | |
| FX Rate to Reporting Currency | 0.30 | 0.30 | 0.30 | 0.30 | 0.30 | 0.30 | |